F8 and hemophilia A: Furthermore, a 2020 International Guideline for treating AHA recommended recombinant porcine factor VIII as an alternative to bypassing agents. Conversely, emicizumab is a recombinant, humanized, bispecific monoclonal antibody with FVIII-mimetic activity that may be administered as prophylaxis to hemophilia A patients with or without factor VIII inhibitors to avoid or lessen the frequency of bleeding episodes [3].